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Purpose: To assess the safety and efﬁcacy of an expanded polytetraﬂuoroethylene stent graft versus balloon angioplasty for the
treatment of in-stent restenosis in the venous outﬂow of hemodialysis access grafts and ﬁstulae.
Materials and Methods: Two hundred seventy-ﬁve patients were randomized at 23 US sites to stent-graft placement or
percutaneous transluminal angioplasty (PTA). Primary study endpoints were access circuit primary patency (ACPP) at 6 months
and safety through 30 days; secondary endpoints were evaluated through 24 months.
Results: ACPP at 6 months was signiﬁcantly higher in the stent-graft group (18.6%) versus the PTA group (4.5%; Po .001), and
freedom from safety events (30 days) was comparable (stent graft, 96.9%; PTA, 96.4%; P ¼ .003 for noninferiority). The separation
in ACPP survival curves remained through 12 months (stent graft, 6.2%; PTA, 1.5%). Treatment area primary patency (TAPP)
was superior for the stent-graft group (66.4%) versus the PTA group (12.3%) at 6 months (Po .001), with a survivorship difference
in favor of stent-graft placement maintained through 24 months (stent graft, 15.6%; PTA, 2.2%). ACPP and TAPP for the stent-
graft group were better than those for the PTA group when compared within central and peripheral vein subgroups (Po .001). In
central veins, TAPP was 13.6% in the stent-graft group versus 4.3% in the PTA group at 24 months (P o .001).
Conclusions: Stent-graft use provided better ACPP and TAPP than PTA when treating in-stent restenosis in patients receiving
dialysis with arteriovenous grafts and ﬁstulae.
ABBREVIATIONS
ACPP = access circuit primary patency, AV = arteriovenous, CEC = clinical events committee, CI = conﬁdence interval, ePTFE =
expanded polytetraﬂuoroethylene, HR = hazard ratio, IPF = index of patency function, ITT = intent-to-treat, KDOQI = Kidney
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Falk et al ’ JVIR1466 ’ RESCUE Study Results: Stent Graft vs Balloon Angioplastyelastic recoil after PTA, when a stenosis recurs within 3
months, in patients at increased risk with surgery, or
following vessel rupture (1). In-stent restenosis accounts
for as many as 73% of cases of restenosis in the
hemodialysis access circuit resulting in reduced blood
ﬂow and loss of arteriovenous (AV) access patency in
patients who require hemodialysis (2–4). The KDOQI
guidelines do not provide recommendations for the
treatment of in-stent restenosis, and, to date, we are
aware of no clinical studies examining the best treat-
ment options. Stent grafts may help reduce the
recurrence of in-stent restenosis by providing a barrier
to intimal hyperplasia. Preclinical work with a
polytetraﬂuoroethylene-covered stent demonstrated that
an inert barrier prevented mediators from leading to an
accelerated proliferative response; the stent-graft group
exhibited less neointimal hyperplasia (P o .001) and
less luminal narrowing (P o .01) than the bare-
metal stent group (5). Clinically, use of an expanded
polytetraﬂuoroethylene (ePTFE) stent graft to treat
venous anastomotic stenoses in patients with a
prosthetic hemodialysis graft improved outcomes
compared with balloon angioplasty alone; the 6-month
primary patency rate at the site of treatment was 51%
when using a stent graft, compared with 23% when
treated with angioplasty (P o .001), whereas the
primary patency rates of the overall access circuit were
38% versus 20%, respectively (P ¼ .008) (6). The present
study was designed to expand on these ﬁndings and
evaluate the use of an ePTFE stent graft for the
treatment of in-stent restenosis in the venous outﬂow
circuit.MATERIALS AND METHODS
Study Design and Oversight
The RESCUE study (Randomized Study of the Fluency
Plus Endovascular Stent Graft in the Treatment of
In-Stent Restenosis in the AV Access Venous Outﬂow
Circuit), a prospective, multicenter, randomized, con-
currently controlled clinical trial, was designed to assess
stent-graft use following balloon predilation compared
with PTA alone in the treatment of in-stent restenosis in
the access circuit of patients receiving hemodialysis with
an AV graft or native ﬁstula. The protocol was approved
by the Food and Drug Administration and institutional
review board at each study site. The RESCUE study was
sponsored by Bard Peripheral Vascular (Tempe, Ari-
zona) and was conducted under an investigational device
exemption in accordance with the guidelines of good
clinical practice and requirements of the Health Insur-
ance Portability and Accountability Act. Patients were
informed of the risks and beneﬁts of participation in the
study, and each provided written informed consent
before being enrolled. Data were collected by on-site
investigators, and Novella Clinical (Morrisville, NorthCarolina), a contract research organization, performed
the statistical analyses. The Yale Angiographic Core
Laboratory (New Haven, Connecticut) analyzed the
angiographic ﬁlms, an independent clinical events com-
mittee (CEC) adjudicated the clinical data, and a data
safety monitoring board provided safety oversight.
The RESCUE trial was registered on clinicaltrials.gov
(ID code NCT01257438) before the start of patient
enrollment.
Inclusion and exclusion criteria are listed in Table 1.
Patients eligible for inclusion in the trial had an in-stent
stenosis (4 50%) in the venous outﬂow circuit of a
mature ﬁstula (per KDOQI guidelines) (1) or an AV
access graft (implanted 4 30 d). Exclusion crite-
ria included a concomitant thrombosis at the treat-
ment site, stenosis crossing the elbow, or a stenosis in
the cannulation zone, cephalic arch, or superior vena
cava.
Study Endpoints and Deﬁnitions
Primary objectives were to evaluate whether the use of
a stent graft was more effective in treating in-stent
restenosis than PTA alone and whether stent-graft use
was at least as safe as PTA (ie, noninferior). The
primary efﬁcacy endpoint was access circuit primary
patency (ACPP) at 6 months, deﬁned as the interval
from treatment until the next thrombosis or repeat
intervention anywhere in the access circuit. The pri-
mary safety endpoint was freedom from any localized
or systemic safety event through 30 days that affected
the AV access circuit and resulted in surgery, hospital-
ization, or death (excluding stenosis or thrombosis,
which was captured in the calculation of ACPP).
Secondary efﬁcacy measures included binary restenosis
(Z 50% diameter stenosis; calculated by the angio-
graphic core laboratory from a 90-d angiogram),
ACPP, treatment area primary patency (TAPP; ie, the
interval from treatment until repeat intervention at the
original treatment site), and index of patency function
(IPF; ie, the time from the study procedure to access
abandonment divided by the number of repeat inter-
ventions performed on the access circuit to maintain
vascular access) through 24 months. Secondary safety
measures included freedom from any safety event
through 24 months (adjudicated by the CEC) and
patient deaths, as reviewed by the CEC and data safety
monitoring board.
Patient Demographics, Access Data, and
Baseline Characteristics
A total of 275 patients were prospectively enrolled at 23
sites between February 2, 2010, and October 7, 2013.
Patients were randomly assigned at a 1:1 ratio to the
stent-graft group (n ¼ 132) and PTA group (n ¼ 143).
Baseline patient demographics, preexisting medical con-
ditions, and clinical indicators were typical for patients
Table 1 . RESCUE Trial Inclusion and Exclusion Criteria
Inclusion Criteria
1. Voluntarily signed/dated informed consent before performance of study procedures;
2. Male or nonpregnant female Z 21 y old with life expectancy sufﬁcient to complete the study;
3. Willingness to comply with study requirements and follow-up procedures;
4. AV access graft (Z 30 d) or mature ﬁstula* located in an arm with at least one successful dialysis session before study procedure;
5. Angiographic evidence of a previously placed BMS located in the venous outﬂow of the AV access circuit;
6. Z 50% stenosis in BMS extending o 3 cm outside BMS;
7. Target lesion r 10 cm in length;
8. Lesion was amenable to angioplasty (angiographically assessed);
9. Reference diameter at the lesion between 5.0 mm and 12.0 mm;
10. Additional stenotic lesions (Z 50%) in the venous outﬂow that were 4 3 cm from the study lesion had to be treated before study
procedure.
Exclusion Criteria
1. Thrombosis treated at lesion site o 7 d before study procedure;
2. Reference diameter at lesion site 4 12.0 mm;
3. Infected AV access graft/ﬁstula or uncontrolled systemic infection;
4. Pseudoaneurysm at target lesion;
5. Location of target lesion required stent graft to be deployed across the elbow joint, at a needle puncture site (ie, “cannulation zone”),
across the cephalic arch, in superior vena cava, or across an angle 4 901;
6. Restenosed BMS fractured (veriﬁed by angiography);
7. Patient had known uncontrolled blood coagulation disorder, allergy or sensitivity to contrast media that could not be adequately
premedicated, hypersensitivity to nickel-titanium alloy, or another medical condition that could impact protocol compliance,
confound data interpretation, or shorten life expectancy (insufﬁcient to complete the study);
8. Concurrent participation in an investigational drug or device study whereby treatment was not complete or treatment interfered with
study endpoints
AV ¼ arteriovenous; BMS ¼ bare metal stent; RESCUE ¼ Randomized Study of the Fluency Plus Endovascular Stent Graft in the
Treatment of In-Stent Restenosis in the Arteriovenous Access Venous Outﬂow Circuit.
*A mature native ﬁstula, as deﬁned by Kidney Disease Outcomes Quality Initiative guidelines (1), has a ﬂow of approximately 600 mL/
min, is less than 0.6 cm below the surface of the skin, and has a minimal diameter of 0.6 cm. The ﬁstula had to be mature and able to
receive hemodialysis treatment.
Volume 27 ’ Number 10 ’ October ’ 2016 1467with end-stage renal disease and were similar between
treatment groups (Table 2). The mean age of patients
was 61.9 years, 51.3% were male, 56.7% were black,
65.8% had diabetes mellitus, and 93.8% had hyper-
tension. The type and location of AV access was
equally distributed between the two groups, with 46.2%
of patients receiving a synthetic graft, 53.8% an
autogenous ﬁstula, and 86.2% an access in the upper
arm (Table 3). Characteristics of the in-stent restenoses
were similar between the study groups (Table 3), and
restenoses were located in the peripheral veins (64.0%)
and central veins (34.9%). The mean stenosis length was
3.0 cm  1.7 and extended an average of 2.5 cm into the
stent. The average stent length was 5.9 cm (median, 6
cm), with a mean diameter of 10.4 mm (median, 10 mm).
The mean reference vessel diameter at the site of
restenosis was 9.4 mm, with a mean percent diameter
stenosis before treatment of 70.7%. Eighty-one patients
in the PTA group and 68 patients in the stent-graft
group had additional stenoses (4 50%) that were at least
3 cm away from the treatment area in the study; overall,
49 of these patients had two additional stenoses and 11
had three additional stenoses. All were treated andshowed a residual stenosis of o 30% before treatment
in the study.Study Procedures and Follow-up
Investigators chose the type and size of angioplasty
balloons as well as inﬂation times; specialty balloons
such as cutting or scoring balloons were not allowed. To
minimize bias associated with knowledge of the treat-
ment assignment, randomization occurred after the
initial PTA procedure. Anatomic and target stenosis
criteria were assessed by angiography, and, if eligible,
the patient was randomized to the intent-to-treat (ITT)
population. The mean maximum balloon inﬂation pres-
sure was 17 atm (range, 7–45 atm). If the patient was
assigned to the PTA group, the remainder of the
procedure was completed per the investigator’s standard
PTA protocol; multiple balloon inﬂations were allowed.
Patients randomized to the stent-graft group received a
Fluency Plus stent graft (Bard Peripheral Vascular,
Tempe, Arizona) after an initial angioplasty. The
stent graft consisted of a self-expanding nitinol stent
encapsulated in ePTFE. The device was available in
Table 2 . Baseline Patient Demographics, Medical History, and Clinical Indicators
Variable Stent Graft (n ¼ 132) PTA (n ¼ 143) Pooled (N ¼ 275)
Patient demographics*
Age (y) 61.1  13.5 62.6  13.6 61.9  13.5
Sex
Male 68 (51.5) 73 (51.0) 141 (51.3)
Female 64 (48.5) 70 (49.0) 134 (48.7)
Race†
White 57 (43.2) 50 (35.0) 107 (38.9)
Black 72 (54.5) 84 (58.7) 156 (56.7)
Asian/Native American‡ 2 (1.5) 7 (4.9) 9 (3.3)
Medical history
Hypertension 136 (95.1) 122 (92.4) 258 (93.8)
Diabetes mellitus 91 (68.9) 90 (62.9) 181 (65.8)
Coronary artery disease 53 (40.2) 44 (30.8) 97 (35.3)
Congestive heart failure 37 (28.0) 39 (27.3) 76 (27.6)
Cerebrovascular accident 27 (20.5) 19 (13.3) 46 (16.7)
PVD 14 (10.6) 17 (11.9) 31 (11.3)
TIA 5 (3.8) 7 (4.9) 12 (4.4)
Glomerulonephritis 5 (3.8) 4 (2.8) 9 (3.3)
Steal syndrome 4 (3.0) 3 (2.1) 7 (2.5)
Hypercoagulation 1 (0.8) 3 (2.1) 4 (1.5)
Clinical indicators
Abnormal physical§ 66 (50.0) 67 (46.9) 133 (48.4)
Decreased access ﬂow 24 (18.2) 18 (12.6) 42 (15.3)
Prolonged bleeding 24 (18.2) 31 (21.7) 55 (20.0)
Abnormal pressure 12 (9.1) 21 (14.7) 33 (12.0)
Difﬁcult needle puncture 5 (3.8) 10 (7.0) 15 (5.5)
Pulling thrombus 4 (3.0) 3 (2.1) 7 (2.5)
Poor dialysis clearance 4 (3.0) 1 (0.7) 5 (1.8)
Note–Values presented as mean  standard deviation where applicable. Values in parentheses are percentages.
PTA ¼ percutaneous transluminal angioplasty; PVD ¼ peripheral vascular disease; TIA ¼ transient ischemic attack.
nThere were no signiﬁcant differences between the groups (P 4 .05).
†Race was self-reported (P ¼ .741, Z-test)
‡Includes Asian, native Hawaiian, Paciﬁc Islander, native Alaskan, and Native American.
§Deﬁned as pulsatile access, discontinuous thrill, edema, collateral veins, altered thrill, or pulse in outﬂow vein.
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and in lengths of 40–120 mm in 20-mm increments, was
premounted on a coaxial delivery catheter, and was
deployed through a 9- or 10-F sheath. Following
deployment, the stent graft was postdilated with a
balloon no larger than the previously placed stent
(mean diameter, 8.7 mm; range, 4–14 mm). Study
procedures were documented in the patient’s medical
records, and trial data were recorded on electronic case
report forms. Telephone assessments were completed at
30 days after the procedure to determine whether the
AV graft or ﬁstula was still functioning and whether
there had been any interventions or adverse events.
Angiograms were obtained during the procedure,
immediately following the procedure, and at 90 days
with two views at least 301 apart with a radiopaque
graduated ruler in the ﬁeld of view; ﬁlms were sub-
mitted to the angiographic core laboratory for analy-
sis. Clinical examinations at the study site were alsocompleted at 90 days and 6 months to assess access
circuit patency and to again determine whether there
had been any interventions or adverse events. On-site
clinical examinations or telephone interviews with the
patient and/or the dialysis center were conducted at 12,
18, and 24 months. At 12 months, the dialysis center
was contacted in 82.5% of cases, 50.5% of patients were
interviewed directly, and 36.4% of patients (100 of 275)
were also seen in clinic. At 24 months, the dialysis clinic
was contacted in 65.5% of cases, 54.2% of patients were
interviewed directly, and 18.5% of patients (51 of 275)
were seen in clinic.Statistical Analysis
A sample size of 220 patients was calculated to provide
the study with 80% power to detect a between-group
difference of 50% in the primary efﬁcacy endpoint at 6
months. This was based on estimated ACPP rates from
Table 3 . Access Type, Treatment Location, Baseline Characteristics, and Procedural Results
Variable Stent Graft (n ¼ 132) PTA (n ¼ 143) Pooled (N ¼ 275)
Access type*
Synthetic graft 62 (47.0) 65 (45.5) 127 (46.2)
Loop conﬁguration† 23 (37.1) 23 (35.4) 46 (36.2)
Straight conﬁguration 39 (63.0) 42 (64.6) 81 (63.8)
Graft length (cm) 21.6  15.9 25.0  18.6 23.2  17.0
Graft diameter (mm) 6.5  1.0 6.4  1.2 6.5  1.1
Mature ﬁstula‡ 70 (53.0) 78 (54.5) 148 (53.8)
Brachiocephalic§ 20 (28.6) 34 (43.6) 54 (36.5)
Transposed brachial 20 (28.6) 16 (20.5) 36 (24.3)
Brachiobasilic 20 (28.5) 13 (15.7) 33 (24.4)
Radiocephalic 3 (4.3) 3 (3.8) 6 (4.1)
Other ﬁstula types 7 (10.0) 12 (15.4) 19 (12.8)
Access position
Upper arm 111 (84.1) 126 (88.1) 237 (86.2)
Forearm 21 (15.9) 17 (11.9) 38 (13.8)
Time since creation (mo)|| 34.4  23.7 41.3  27.1 38.0  25.7
Time since dialysis (d)¶ 2.2  0.6 2.2  0.7 2.2  0.7
Stent location
Central vein 41 (31.1) 55 (38.5) 96 (34.9)
Subclavian vein 30 (22.7) 43 (30.1) 73 (26.5)
Brachiocephalic vein 10 (7.6) 12 (8.4) 22 (8.0)
Superior vena cava 1 (0.8) 0 1 (0.4)
Peripheral vein 90 (68.2) 86 (60.1) 176 (64.0)
Axillary region 44 (33.3) 33 (23.1) 77 (28.0)
Venous anastomosis 29 (22.0) 28 (19.6) 57 (20.7)
Within ﬁstula body 10 (7.6) 9 (6.3) 19 (6.9)
Cephalic vein outﬂow 5 (3.8) 11 (7.7) 16 (5.8)
Intragraft 2 (1.5) 3 (2.1) 5 (1.8)
Arterial anastomosis 0 2 (1.4) 2 (0.7)
Location not reported 1 (0.8) 2 (1.4) 3 (1.1)
Baseline characteristic
Stenosis length (cm) 3.2  1.8 2.9  1.7 3.0  1.7
Bare-metal stent length (cm) 5.9  1.9 6.0  2.4 5.9  2.2
Distance in stent (cm)# 2.6  1.6 2.3  1.7 2.5  1.6
Stent diameter (mm) 10.0  2.2 10.7  4.8 10.4  3.8
Average RVD (mm)** 9.2  1.7 9.5  2.0 9.4  1.8
Diameter stenosis (%)†† 71.5  13.2 69.9  13.8 70.7  13.5
Procedural results
Fluoroscopy time (min) 5.6  4.0 4.3  3.7 4.9  3.9
Procedure time (min) 34.0  19.2 27.4  21.1 30.5  20.5
Residual diameter stenosis (%)‡‡ 15.4  12.7 18.3  11.6 –
Note–Values presented as mean  standard deviation where applicable. Values in parentheses are percentages.
PTA ¼ percutaneous transluminal angioplasty; RVD ¼ reference vessel diameter.
nAdjudicated by angiographic core laboratory.
†Based on the percentage of synthetic grafts.
‡A mature native ﬁstula, as deﬁned by Kidney Disease Outcomes Quality Initiative guidelines (1), has a ﬂow of approximately 600 mL/
min, is less than 0.6 cm below the surface of the skin, and has a minimal diameter of 0.6 cm. The ﬁstula had to be mature and able to
receive hemodialysis treatment.
§Based on the percentage of mature ﬁstulae.
¶Mean time since access graft implantation or ﬁstula creation.
||Mean time since last dialysis session.
#Distance of the restenosis into the bare-metal stent.
nnReference vessel diameter at the restenosis of the bare-metal stent.
††Percent diameter stenosis in the previously placed bare-metal stent.
‡‡Percent diameter stenosis remaining after the study treatment procedure.
Volume 27 ’ Number 10 ’ October ’ 2016 1469
Falk et al ’ JVIR1470 ’ RESCUE Study Results: Stent Graft vs Balloon Angioplastythe literature of 15% for the PTA group and 30% for the
stent-graft group at 6 months (2,6,7), and was adjusted
by 9% to account for missing (ie, censored) data.
The primary efﬁcacy and safety endpoints were
analyzed on an ITT basis. A Kaplan–Meier analysis
was used to estimate the survival of ACPP in the stent-
graft and PTA groups; missing data were censored at 6
months in the estimation of the percentage of patients
with ACPP. Data are presented as a mean rate and 95%
conﬁdence interval (CI), with a two-sided P value of .05
used to determine statistical signiﬁcance between the two
treatment groups. Within-stratum (ie, AV graft, AV
ﬁstula, central vein, peripheral vein) differences between
the stent-graft and PTA groups were determined by
using the Hochberg multiple-comparisons adjustment
(one-sided P value of .025) and are reported as a mean
rate and the 95% CI. The primary safety endpoint at 30
days was analyzed with a Farrington–Manning test for
noninferiority of proportions (one-sided test, α = .05)
with a noninferiority margin of 7.5%. The 30-day free-
dom from safety event is presented as an estimated mean
survival and the 95% CI. TAPP was prespeciﬁed in the
protocol to be hypothesis-tested at 6 months; a Kaplan–
Meier analysis with a two-sided P value of .05 was used
to determine statistical signiﬁcance between the two
treatment groups, and the Hochberg multiple compar-
isons adjustment was used to compare within-stratum
differences. TAPP is reported as the mean rate with the
95% CI. Other secondary endpoints are presented as
estimates of survival based on Kaplan–Meier time-to-
event analyses; IPF is presented as the number of days to
access abandonment divided by the number of visits for
repeat intervention; binary restenosis is presented as a
proportional rate (percentage) with the 95% CI. The
secondary-endpoint differences reported beyond 6
months (12 and 24 mo) were not prespeciﬁed for
hypothesis testing or controlled for multiplicity and
should be considered exploratory rather than conﬁrma-
tory evidence.
Continuous variables were compared with the use of
Student t tests, Z-tests were used for proportions,
Wilcoxon nonparametric tests were used for means,
and categoric variables were compared with the use of
the χ2 test for proportions. All statistical analyses were
performed by using SAS software (version 9.2 or higher;
SAS, Cary, North Carolina).RESULTS
Procedural results are presented in Table 3. In the PTA
group, 88.1% of patients were treated with one
angioplasty balloon; 11.0% needed two and 0.9%
needed three PTA balloons to efface the restenosis. In
the stent-graft group, the most common device diameters
were 8 mm (30.5%) and 9 mm (23.4%), and 40 mm
(33.6%) and 60 mm (44.5%) were the most commonlengths. A 9-F sheath was used for stent-graft placement
in 71% of cases, with a 10-F sheath used 28% of the time.
Mean residual percent stenoses after the procedure were
15.5%  12.8 for the stent-graft group and 18.4%  11.8
for the PTA group. During the procedure, venous
rupture occurred in two cases in the PTA group (1.5%)
and in one in the stent-graft group (0.8%). Successful
balloon tamponade was performed in all cases, and a
bare-metal stent was placed in one patient in the PTA
group following tamponade. No devices failed or mal-
functioned at deployment.
Postprocedure Follow-up
The disposition of patients in the RESCUE study is
outlined in Figure 1. Of the 275 patients enrolled in the
study, 199 completed 24-month follow-up (97 with a
stent graft, 102 with PTA). Seventy-six patients, 35 in the
stent-graft group and 41 in the PTA group, were lost to
follow-up or missing ﬁnal data (n ¼ 14), withdrew
consent or were withdrawn by the study investigator
(n ¼ 4), or died (n ¼ 58). Regression analyses demon-
strated no differences in primary-efﬁcacy (P ¼ .09) or
safety (P ¼ 1.0) endpoints between study sites, so all
data were pooled for analysis.
Primary Efﬁcacy and Safety Outcomes
Kaplan–Meier curves for the primary efﬁcacy endpoint
(ie, ACPP) are presented in Figure 2. The probability of
maintaining ACPP was signiﬁcantly higher in the stent-
graft group (18.6%) than in the PTA group (4.5%; P o
.001) at 6 months after the procedure (Table 4). In
addition, the estimated ACPP hazard ratio (HR) based
on a Cox regression model demonstrated that use of the
stent graft reduced the risk of ACPP failure by 38%
compared with PTA alone (HR ¼ 0.62; P o .05).
Prespeciﬁed subgroup analyses of patients with AV
synthetic grafts versus autogenous ﬁstulae and patients
with central-vein versus peripheral-vein locations are
summarized in Table 4. Within each individual
subgroup (ie, AV graft, AV ﬁstula, central vein, and
peripheral vein), patients treated with a stent-graft
exhibited signiﬁcantly better ACPP than patients treated
with PTA alone (P o .02).
The primary safety endpoint, the percentage of
patients free from safety events through 30 days, was
96.9% in the stent-graft group, compared with 96.4% in
the PTA group, which met the prespeciﬁed criterion for
noninferiority (δ ¼ 0.075) between treatment groups
(P ¼ .003 for noninferiority; Table 4). Noninferiority
between the stent-graft and PTA groups observed in
the overall population was also observed within the
AV graft and ﬁstula subgroups (Table 4). In addition,
estimates from a logistic regression model that
accounted for treatment group (ie, stent-graft or PTA
only) and type of access (ie, synthetic graft or ﬁstula) for
the overall population demonstrated no signiﬁcant
Figure 1. RESCUE trial patient disposition.
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ratio estimate, 0.86).Secondary Outcomes
Secondary efﬁcacy endpoints (eg, binary restenosis,
TAPP, IPF) are summarized through 24 months in
Table 5. An area in the access circuit with a Z 50%
diameter stenosis determined by angiographic follow-up
at 90 days was characterized as restenotic; binary
restenosis rates (adjudicated by the core laboratory)
were 19.7% for the stent-graft group and 73.4% for the
PTA group.
Prespeciﬁed hypothesis testing was completed for
TAPP at 6 months, and Kaplan–Meier curves arepresented in Figure 3. As was the case for the overall
access circuit, the probability of maintaining patency at
the site of the treated restenosis (ie, TAPP) was superior
for the stent-graft group (66.4%) compared with the
PTA group (12.3%) at 6 months after the procedure
(P o.001). Cox regression estimates demonstrated that
the use of the stent graft reduced the risk of TAPP failure
by 79% compared with PTA alone (HR ¼ 0.21). The
Kaplan–Meier curves for TAPP showed a difference in
survivorship between the treatment groups through 24
months, with a steeper decline in the PTA group curve
(Fig 3). TAPP for the stent-graft group was 32.7%,
compared with 5.6% for the PTA group, at 12 months,
and this difference was maintained at 24 months (stent
graft, 15.6%; PTA, 2.2%). When TAPP rates for the
Figure 2. ACPP through 24 months. Kaplan–Meier curves are presented for both treatment groups, and represent the probability of
maintaining ACPP through 24 months. The Kaplan–Meier table provides the number of patients at risk, patients censored (eg, death,
loss to follow-up), and patients who experienced an event that ended ACPP at time intervals through 24 months. The P value is based
on a one-sided, stratiﬁed log-rank test.
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the prespeciﬁed access type (ie, AV graft and AV ﬁstula) and
location (ie, central vein and peripheral vein) subgroups,
patients with stent grafts had signiﬁcantly better TAPP than
those treated with PTA (P o .001) for all subgroups
(Table 4). For example, when stratiﬁed by location in the
central veins, TAPP at 6 months for the stent-graft group
was 63.4%, compared with 4.3% for PTA (P o .001). This
difference between the stent-graft group and PTA group in
central veins was observed through 24 months (stent graft,
13.6%; PTA, 4.3%; P o .001).
Secondary analyses demonstrated a difference in
ACPP survivorship curves between the treatment groups
through 12 months; ACPP for the stent-graft group was
6.2%, compared with 1.5% for the PTA group, at 12
months (Fig 2). At 24 months, this survival difference
was not maintained, and ACPP was near zero for both
groups (stent-graft group, 0.9%; PTA group, 0.8%). As
was the case with the overall ITT group, ACPP
appeared better for the stent-graft group than the PTA
group through 12 months when stratiﬁed by location.
ACPP in the central veins was 7.5% for the stent-graft
group at 12 months, compared with 2% in the PTA
group (P ¼ .02), and ACPP in the peripheral veins at 12months was 5.7% for the stent-graft, group compared
with 1.2% for the PTA group (P ¼ .002).
The mean IPFs, deﬁned as the time from the study
procedure to access site abandonment divided by the
number of repeat interventions on the AV access circuit
or at the target restenosis, were 178 days  152 for the
stent-graft group versus 143 days  109 for the PTA
group for the access circuit, and 290 days  219 for the
stent-graft group versus 192 days  157 for the PTA
group at the treatment site, at 24 months.
Incidences of freedom from any safety event in the
ITT population through 24 months were 86% for the
stent-graft group and 84.8% for the PTA group
(Table 5). Overall, through 24 months, 44 safety events
adjudicated by the CEC were reported in 36 patients: 21
events in 17 patients in the stent-graft group and 23
events in 19 patients in the PTA group. Major compli-
cations that resulted in death occurred in four stent-graft
recipients (3%) and four PTA recipients (2.8%); however,
none were adjudicated by the CEC as device- or
procedure-related. Overall, the all-cause death rate
(21%) and the rates of major complications were com-
parable between treatment groups, with no notable
differences in the rates of safety events.
Table 4 . Primary and Hypothesis-Tested Endpoints
Endpoint Stent Graft (n ¼ 132) PTA (n ¼ 143) P Value HR
Primary efﬁcacy endpoint: 6-mo ACPP*, % 18.6 (11.9–25.4) 4.5 (1.0–8.0) o .001† 0.62‡
6-mo ACPP stratiﬁed by access type/location
AV graft only§ 20.0 (9.9–30.2) 1.6 (0.0–4.8) .01 0.63
AV ﬁstula only|| 17.4 (8.5–26.4) 6.9 (1.1–12.8) .003 0.62
Central vein¶ 17.5 (5.7–29.3) 2.0 (0.0–6.0) .02 0.62
Peripheral vein# 19.3 (11.1–27.6) 6.1 (0.9–11.3) .003 0.63
Hypothesis-tested secondary efﬁcacy endpoint: 6-mo TAPP, %** 66.4 (58.0–74.7) 12.3 (6.6–18.0) o .001 0.21††
6-mo TAPP stratiﬁed by type of access and location
AV graft only 57.4 (44.7–70.1) 7.7 (0.8–14.6) o .001 0.24
AV ﬁstula only 74.5 (64.0–85.0) 16.2 (7.5–24.9) o .001 0.19
Central vein 63.4 (48.1–78.8) 4.3 (0.0–10.1) o .001 0.18
Peripheral vein 68.5 (58.6–78.3) 16.1 (7.9–24.2) o .001 0.21
Primary safety endpoint‡‡: 30-d freedom from any safety event, %||||
Overall¶¶ 96.9 (92.3–99.2) 96.4 (91.8–98.9) .003## –
AV graft subgroup 100.0 (94.0–100) 98.4 (91.5–100) – –
AV ﬁstula subgroup 94.3 (86.0–98.4) 94.7 (87.0–98.6) – –
Note–Values in parentheses are percentages where applicable. Ranges in parentheses are 95% conﬁdence intervals.
ACPP ¼ access circuit primary patency; AV ¼ arteriovenous; HR ¼ hazard ratio; PTA ¼ percutaneous transluminal angioplasty; TAPP
¼ treatment area primary patency.
*Interval from the treatment procedure until the next access thrombosis or repeat intervention anywhere in the access circuit from the
arterial inﬂow to the superior vena cava/right atrium junction.
†P value (one-sided) based on a stratiﬁed log-rank test.
‡Proportional-hazards regression model with treatment group as a covariate. The reduction in the risk of failure of ACPP as a result of
the use of the stent graft versus PTA only was 38%.
§n ¼ 61 patients in the stent-graft group and n ¼ 65 in the PTA-only group with AV synthetic grafts.
||n ¼ 71 patents in the stent-graft group and n ¼ 78 in the PTA-only group with AV ﬁstula only.
¶n ¼ 41 patients in the stent-graft group and n ¼ 55 in the PTA-only group with central vein placement.
#n ¼ 90 patients in the stent-graft group and n ¼ 86 in the PTA-only group with peripheral vein placement.
**Interval after the treatment procedure until the next repeat intervention at the original treatment site or until the access circuit was
abandoned.
††Proportional-hazards regression model with treatment group as a covariate. The reduction in the risk of failure of PLP as a result of
the use of the stent graft vs PTA only was 79%.
‡‡All adverse events were reviewed by a blinded clinical events committee.
||||Freedom through 30 d from any adverse event localized or systemic that reasonably suggests the involvement of the AV access
circuit that requires or results in additional interventions (including surgery), in-patient hospitalization, prolongation of an existing
hospitalization, or death.
¶¶Ten safety events occurred in nine patients through 30 d: four patents had ﬁve events in the stent-graft group and ﬁve patients had
ﬁve events in the PTA group.
##P value is based on a noninferiority Farrington and Manning exact test with a noninferiority margin of 0.075 (or 7.5%).
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All AV access circuits, ﬁstulae and grafts, develop
neointimal hyperplastic stenoses that cause access dys-
function by obstructing blood ﬂow, decreasing the
efﬁciency of hemodialysis, and increasing the risk of
access thrombosis. KDOQI guidelines maintain that
6-month primary patency rates with the use of balloon
angioplasty, the ﬁrst-line treatment for access circuit
dysfunction, should be at least 50% (1). However,
randomized studies have shown much lower rates
with PTA alone, with 23%–40% requiring repeated
interventions to maintain patency (6,8). The routine
use of intravascular bare-metal stents to treat stenoses
can provide an effective short-term treatment option, but
prospective (9) and randomized trials (10,11) have not
demonstrated improved longer-term access patency. Inaddition, retrospective observational studies have shown
the need for repeated interventions to maintain stent
patency in central and peripheral veins (3,12–14).
Stent grafts theoretically provide a combination of
endoluminal support to maintain vessel wall patency and
a biocompatible barrier to prevent cellular ingrowth.
Improved patency results have been shown with covered
stents in prospective, randomized trials comparing PTA
versus stent-graft placement in the treatment of AV graft
stenoses. Haskal et al (6), in a prospective, randomized
comparison of an ePTFE stent graft and PTA alone
for revision of stenoses at the AV graft/venous
anastomosis, demonstrated superior patency, fewer
repeat interventions, and a signiﬁcantly lower binary
restenosis rate when using the stent graft. The 6-month
TAPP rates were 51% in the stent-graft group versus
23% with PTA (P o .001), and ACPP at 6 months was
Table 5 . Secondary Endpoints
Endpoint Stent Graft (n ¼ 132) PTA (n ¼ 143) P Value*
Procedure success† 128 (97.0) 137 (95.8) –
90-d binary restenosis‡ 26 (19.7) 105 (73.4) –
ACPP (%)
12-mo ACPP 6.2 (2.0–10.4) 1.5 (0.0–3.6) –
Central vein 7.5 2.0 .02
Peripheral vein 5.7 1.2 .002
24-mo ACPP 0.9 (0.0–2.6) 0.8 (0.0–2.2) –
Central vein 1.1 0.0 –
Peripheral vein 0.0 2.0 –
TAPP (%)
12-mo TAPP 32.7 (24.2–41.2) 5.6 (1.5–9.7) –
Central vein 30.3 4.3 o .001
Peripheral vein 31.5 5.0 o .001
24-mo TAPP 15.6 (8.6–22.7) 2.2 (0.0–5.2) –
Central vein 13.6 4.3 o .001
Peripheral vein 16.5 1.7 o .001
IPF§
6 mo 141.6  51.2 128.8  55.1 –
12 mo 165.9  104.8 132.1  82.8 –
24 mo 177.9  152.3 143.2  109.3 –
Safety endpoints through 24 mo
Freedom from any safety event (%)
12 mo 89.8 (84.5–95.1) 90.1 (85.0–95.3) –
24 mo 86.0 (79.8–92.2) 84.8 (78.5–91.2) –
All AEs|| 38 47
Patients with any AE 27 (20.5) 38 (26.6) –
All-cause death¶ 26 (19.7) 32 (22.4) –
Note–Values in parentheses are percentages where applicable. Ranges in parentheses are 95% conﬁdence intervals. Values presented
as means  standard deviation where applicable.
ACPP ¼ access circuit primary patency; AE ¼ adverse event; IPF ¼ index of patency function; PTA ¼ percutaneous transluminal
angioplasty; TAPP ¼ treatment area primary patency.
nAll P values provided as part of the secondary analyses, except for 6-mo PLP presented in Table 4, were post-hoc and exploratory in
nature. The P values were used to assess possible trends but are not conﬁrmatory values of superiority.
†Procedure success denotes anatomic success (o 30% residual stenosis) and resolution of preprocedural clinical indicators of a
hemodynamically signiﬁcant stenosis, such as an abnormal physical examination, abnormal pressure monitoring parameters,
decreased access ﬂow, difﬁculty with dialysis needle puncture, pulling thrombus, prolonged bleeding, increased recirculation, and/or
inadequate dialysis clearance.
‡Lesions ofZ 50% diameter stenosis at 90-d follow-up by angiography were characterized as restenotic (determined by angiographic
core laboratory).
§Deﬁned as the number of days for the treatment procedure to access abandonment divided by the number of repeat interventions to
maintain vascular access.
||All adverse events involving the AV access circuit that were reported by the investigators from the time of the treatment procedure
onward, regardless of whether the events were classiﬁed by the clinical events committee as safety events.
¶All deaths were reviewed by the data safety monitoring board and adjudicated by the clinical events committee, and none were
classiﬁed as device- or procedure-related. One death in the stent-graft group was classiﬁed as unknown, as the relationship to the
procedure or device could not be determined.
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PTA group (38% vs 20%; P ¼ .008); freedom from
subsequent intervention in the stent-graft group was
32%, versus 16% for the PTA group (P ¼ .03), and the
binary restenosis rate for the stent-graft group was 28%,
compared with 78% for the PTA group (P o .001) (6).
Haskal (15) also reported 24-month ﬁndings from the
RENOVA (A Prospective, Randomized, Concurrently-
Controlled Post-Approval Study of the FLAIR Endo-
vascular Stent Graft) trial using the same ePTFE stentgraft and similar protocol; ACPP for the stent-graft
group (9.5%) was again superior to that for the PTA
group (5.5%; P ¼ .01), as was TAPP (26.9% vs 13.5%,
respectively; P o .001). Data from the REVISE (Via-
bahn Endoprosthesis Versus Percutaneous Transluminal
Angioplasty to Revise AV Grafts in Hemodialysis) trial
(16) also demonstrated that percutaneous revision of
venous anastomotic stenoses in patients with AV grafts
was improved with the use of an ePTFE stent graft,
reporting a 6-month TAPP of 51.6% for the stent-graft
Figure 3. TAPP through 24 months. Kaplan–Meier curves are presented for both treatment groups, and represent the probability of
maintaining TAPP through 24 months. The Kaplan–Meier table provides the number of patients at risk, patients censored (eg, death,
loss to follow-up), and patients who experienced an event that ended TAPP at time intervals through 24 months. The P value is based on
a one-sided, stratiﬁed log-rank test.
Volume 27 ’ Number 10 ’ October ’ 2016 1475group compared with 34.2% with PTA alone (ITT
group), and ACPP at 6 months of 41.5% in the stent-
graft group compared with 28.4% in the PTA group
(P ¼ .035). Finally, a recent small, prospective, random-
ized series comparing ePTFE stent-graft placement
versus PTA for the treatment of cephalic-arch stenoses
in brachiocephalic ﬁstulae (17) demonstrated superior
patency when using a stent graft compared with PTA
alone (Po .01); ACPP and TAPP at 6 months were 0%
for the PTA group and 67% and 100% for the stent-graft
group, respectively.
Based on these encouraging results with stent grafts
used to treat stenoses in the AV access circuit, the
RESCUE trial sought to determine if an ePTFE-
covered stent improved outcomes, speciﬁcally patency
of the access circuit, when used to revise stenoses in
previously placed bare-metal stents. We found that use
of the stent graft following angioplasty for in-stent
restenosis resulted in superior access circuit patency at
6 months compared with PTA alone and was noninferior
with respect to safety; ACPP at 6 months was signiﬁ-
cantly higher in the stent-graft group, at 18.6%, com-
pared with 4.5% in the PTA group (P o .001), with a
difference in survivorship curves between the treatment
groups maintained through 12 months (stent graft, 6.2%;PTA, 1.5%). TAPP was superior for the stent-graft
group (66.4%) compared with the PTA group (12.3%)
at 6 months (P o.001), and this difference in survivor-
ship between the treatment groups remained through 24
months, with a TAPP in the stent-graft group of 15.6%
compared with 2.2% in the PTA group. In addition, the
mean time from the study procedure to access-site
abandonment divided by the number of repeat interven-
tions on the AV access circuit (ie, IPF) was longer for the
stent-graft group (178 d  152) compared with the PTA
group (143 d  109) at 24 months. At early time points
through 6 months, IPFs for both groups were similar,
but, by 2 years, as the cumulative number of repeat
interventions and access abandonments increased, the
difference in IPF favored the stent-graft group.
The RESCUE study was unique compared with
previous stent-graft studies for dialysis access revision
because AV grafts (46%) and AV ﬁstulae (54%) were
included and peripheral (64%) and central vein (35%)
stenoses were treated. There was no signiﬁcant difference
in primary patency at 6 months in terms of ACPP (P ¼
.47) or TAPP (P ¼ .09) when the overall ITT population
was stratiﬁed by type of access. Within-stratum out-
comes (ie, AV graft, AV ﬁstula, central vein restenoses,
and peripheral vein restenoses) for the stent-graft group
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location (Po .02). For example, ACPP at 12 months in
the central vein cohort was 7.5% for the stent-graft
group versus 2% for the PTA group (P ¼ .02), and
TAPP rates at 24 months were 13.6% versus 4.3%,
respectively (P o .001).
To date, the RESCUE study is the only prospective,
randomized clinical trial examining the use of covered
stents for in-stent restenosis in the venous outﬂow circuit
including restenoses in central veins and in native AV
ﬁstulae as well as synthetic grafts. Superior patency
achieved with the use of an ePTFE stent graft in the
central veins provides a treatment option supported by
clinical evidence for this difﬁcult-to-treat group of
patients.
One of the limitations of the present study was that,
contrary to standard clinical practice, a 90-day angio-
gram was required for all patients; angiographic identi-
ﬁcation of a stenosis and subsequent repeat intervention
may have led to an overall lower primary patency rate
than would have been observed in standard clinical
practice. In addition, the all-cause mortality rate in
patients with end-stage renal disease is high (21% in
the present study), and patients have signiﬁcant comor-
bidities that make follow-up difﬁcult. The follow-up rate
in the present study was 72.4% at 24 months; 18.5% were
seen in the clinic and the remainder were followed by
phone interview with the patient or access clinic. Results
reported beyond 6 months were therefore not
hypothesis-tested and should be considered exploratory
in nature. An additional limitation includes the potential
for bias that exists in any manufacturer-sponsored
device trial.
In summary, treatment of in-stent restenosis with a
stent graft in the peripheral or central access circuit in
patients with dysfunctional AV grafts or native ﬁstulae
provided better access circuit and treatment area pri-
mary patency than PTA alone and was also noninferior
to PTA in terms of safety.ACKNOWLEDGMENTS
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